Zion Market Research has published a new report titled “General Anxiety Disorder Market by Therapeutics (Antidepressant, Benzodiazepines and Others): U.S. Industry Perspective, Comprehensive Analysis, and Forecast, 2014 – 2020.” According to the report, The U.S. demand for general anxiety disorder market was valued at USD 3,251 million in 2014 and is expected to generate revenue of USD 3,775 million by end of 2020, growing at a CAGR of 2.4% between 2015 and 2020.
Request Free Sample Research Report @ https://www.zionmarketresearch.com/sample/general-anxiety-disorder-market
General anxiety disorders or generalized anxiety disorders (GAD) usually happen along with other physical or mental illnesses such as alcohol or substance abuse, which might mask anxiety symptoms. In some scenario, these other illnesses treated prior to person respond to treatment for the anxiety disorder. Efficient therapies for general anxiety disorders are present, and ongoing research is uncovering novel treatments that may aid most people with GAD.
Currently, U.S. general anxiety disorders market is saturated as a variety of antidepressant drugs are available on prescription for the similar symptom. Presently, general anxiety disorders market is on a decline owing to a weak pipeline of novel drugs, patent expiry of major antidepressants and an increasing number of cheap generic drug variants in the market. The U.S. stands for the major regional market for anxiety disorder therapeutics worldwide.
Inquire more about this report @ https://www.zionmarketresearch.com/inquiry/general-anxiety-disorder-market
General anxiety disorder market includes several types of therapeutic segments such as antidepressant, benzodiazepines and other therapeutics. The antidepressant was a main therapeutic segment of general anxiety disorder market and accounted 38.6% share of the total demand in 2014. This segment is further expected to continue its dominance in the market over the estimated period. Several kinds of medications employed to treat general anxiety disorder. Antidepressants such as serotonin norepinephrine reuptake inhibitor (SNRI) and selective serotonin reuptake inhibitor (SSRI) classes are the first-line medication treatments. Benzodiazepines are the most common class of anti-anxiety drugs and usually employed only for relieving severe anxiety on a short-term basis. These are medications alleviate anxiety by slowing down the central nervous system. Their calming and relaxing effects have made them very popular in the U.S. They are also prescribed as muscle relaxants and sleeping pills.
Browse detail report with in-depth TOC @ https://www.zionmarketresearch.com/report/general-anxiety-disorder-market
North America emerged as the foremost regional market for the global depression in 2014. This was mostly due to the presence of large population infected with many kinds of depression and anxiety disorders. Some of the renowned players in this market include Eli Lilly and Company, Sanofi S.A. Forest Laboratories, Inc., Johnson & Johnson H. Lundbeck A/S, Merck & Co., Inc., Pfizer, Inc. are some of the dominant players in the market space.
For Media Inquiry contact our sales Team @ firstname.lastname@example.org
Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.